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ABSTRACT 
 The in vitro MultiFlow® DNA Damage Assay multiplexes γH2AX, p53, phospho-histone 
H3, and polyploidization biomarkers into a single flow cytometric analysis [Bryce et al., 2016]. 
The current report describes a tiered, sequential data analysis strategy based on data 
generated from exposure of human TK6 cells to a previously described 85 chemical training set 
and a new pharmaceutical-centric test set (n=40). In each case, exposure was continuous over 
a range of closely spaced concentrations, and cell aliquots were removed for analysis following 
4 and 24 hr of treatment. The data analyses described herein begins with a machine learning 
ensemble in addition to a rubric that considers fold increases in biomarkers against global 
evaluation factors (GEFs)—a positive finding in either is sufficient to make a genotoxic-positive 
call. In the case of a positive finding, tier 1 further considers the machine learning predictions 
and GEFs to classify the activity as clastogenic and/or aneugenic. Test set results demonstrated 
the generalizability of the first tier, as 35/40 (88%) concordance with a priori genotoxicity 
expectations was observed, and 21/24 (88%) of the chemicals identified as genotoxic were 
predicted to exhibit the expected mode of action (MoA). A second tier applies unsupervised 
hierarchical clustering to the biomarker response data, and these analyses were found to group 
certain chemicals, especially aneugens, according to their molecular targets. Finally, a third tier 
utilizes benchmark dose analyses and MultiFlow biomarker responses to rank genotoxic 
potency. The relevance of these rankings is supported by the strong agreement found between 
benchmark dose values derived from MultiFlow biomarkers compared to those generated from 
parallel in vitro micronucleus analyses. Collectively, the results suggest that a tiered MultiFlow 
data analysis pipeline is capable of rapidly and effectively identifying genotoxic hazards while 
providing additional information that is useful for modern risk assessments—MoA, molecular 
targets, and potency. 
INTRODUCTION 
 Our laboratories have pursued the development and validation of a multiplexed flow 
cytometric assay that combines information from several biomarkers relevant to DNA damage 
response pathways and aneuploidy induction [Bryce et al., 2014, 2016, 2017, 2018; Bernacki et 
al., 2016]. This so-called MultiFlow® DNA Damage Assay is formatted as an add-and-read test 
that efficiently prepares cells in microtiter plates for flow cytometric analysis. The biomarkers 
measured are: i) phosphorylation of H2AX at serine 139 (γH2AX) to detect DNA double strand 
breaks, ii) phosphorylation of histone H3 at serine 10 (p-H3) to identify mitotic cells, iii) nuclear 
p53 content as an indicator of p53 activation in response to DNA damage, iv) frequency of 8n+ 
cells to monitor polyploidization, and v) determination of nuclei counts to provide information 
about treatment-related cytotoxicity and cytostasis. Relative to individual, standard in vitro 
genotoxicity assays, an advantage of the MultiFlow method is that it goes beyond genotoxic 
hazard identification, since it is capable of distinguishing between clastogenic and aneugenic 
MoA [Bryce et al., 2016].  
 Given the multiplexed nature of the MultiFlow assay, the data analysis procedures used 
to synthesize and interpret biomarker responses have resembled pattern-recognition tools as 
opposed to parametric and non-parametric pair-wise tests that are commonly applied to 
traditional single endpoint genotoxicity assays. One published example of a MultiFlow data 
analysis strategy makes use of a series of global evaluation factors (GEFs) [Bryce et al., 2017]. 
This approach is based on cutoff response values that were derived for each biomarker and 
time point from data collected by 7 laboratories. To optimize agreement with a priori calls, a 
rubric was developed around the collection of cutoff values that categorizes chemicals as 
genotoxic or not, and if the former, whether the activity is clastogenic, aneugenic, or both. This 
approach was reported to exhibit good sensitivity and specificity across laboratories, and it 
provided reliable MoA information. However, an important caveat is that the initial report did not 
evaluate the method’s performance against chemicals that were outside of the training set, i.e., 
with an external test set that was not used to develop the GEFs and associated rubric.  
 Other data analysis strategies have made use of supervised machine learning tools. In 
this paradigm, mathematical algorithms were developed based on training set data where 
genotoxic potential and MoA are known. The labeled data provided a means to create models 
that could then be used to make predictions based on new biomarker response data that were 
not part of the training set. For instance, most recently, an ensemble of three machine learning 
algorithms consisting of logistic regression, random forest, and an artificial neural network has 
been described [Bryce et al., 2018]. In this case, a majority vote was used to make a final 
prediction about genotoxicity and genotoxic MoA. As with GEFs, this machine learning strategy 
also demonstrated good performance characteristics, but in this case in a more convincing 
fashion, as performance was maintained with an external test set of 103 chemicals.  
 Whereas there are advantages and disadvantages to the GEF and machine learning 
data analysis strategies, their use is not mutually exclusive, and there may be merit to using 
them in combination. The current experiments were therefore designed to extend our work with 
MultiFlow data analysis strategies by testing the performance of the GEF rubric and/or a 
machine learning ensemble using chemicals outside the training set. Furthermore, we 
investigated the utility of hierarchical clustering to group genotoxic chemicals with similar 
molecular targets, and evaluated the capacity of MultiFlow biomarker responses to provide 
genotoxicity potency ranking. For these investigations, MultiFlow data were generated from TK6 
cells exposed to a diverse set of chemicals using a continuous treatment design (i.e., 24 hr), 
and in some cases these analyses were supplemented with in vitro micronucleus 
measurements. The results are discussed in terms of the performance and benefits of a 
sequential, tiered, high information content data analysis pipeline (see Figure 1). 
 
MATERIALS AND METHODS 
Chemicals 
 The identities of 85 previously reported training set chemicals [Bryce et al., 2018] and a 
new set of pharmaceutical-centric test set chemicals (n=40), the source, and other information, 
are provided in Table I. Merck supplied 20 of the 40 test chemicals (coded) to Litron, and these 
were stored at -20°C until they were solubilized in dimethyl sulfoxide (DMSO), at which point 
they were refrozen at -20°C. Additional test set chemicals (n = 20) were selected by Litron 
scientists largely from the list recommended by Kirkland and colleagues for evaluating new 
genotoxicity tests [Kirkland et al., 2016]. Our a priori expectation regarding the in vitro 
mammalian cell genotoxicity potential for each of the 125 chemicals can be found in Table I. As 
explained in more detail below, the experiments reported herein occurred in the absence of an 
exogenous metabolic activation system. Thus, the a priori calls provided in Table I reflect 
expected genotoxicity assay results in the context of an S9-free mammalian assay system.  
 
Cell Culture and Treatments 
 TK6 cells were purchased from ATCC® (cat. no. CRL-8015). Cells were grown in a 
humidified atmosphere at 37°C with 5% CO2, and were maintained at or below 1 x 106 cells/mL. 
The culture medium consisted of RPMI 1640 with 200 µg/mL sodium pyruvate (both from 
Sigma-Aldrich, St. Louis, MO), 200 µM L-glutamine, 50 units/mL penicillin and 50 µg/mL 
streptomycin (from Mediatech Inc., Manassas, VA), and 10% v/v heat-inactivated horse serum 
(Gibco®, a Thermo Fisher Scientific Company, Waltham, MA).  
 Chemicals selected by Litron scientists were tested using the same experimental design 
described previously [Bryce et al., 2016, 2017]. Briefly, treatments occurred in U-bottom 96 well 
plates, with 198 µL TK6 cell suspension (2 x 105/mL) combined with 2 µL of DMSO-solubilized 
test chemical per well. The highest concentration tested was 1 mM, and the 19 additional 
concentrations were tested using a square root dilution scheme—that is, each concentration 
differed from the one above by a factor of 70.71%. In this manner a wide range of 
concentrations were evaluated (i.e., nearly 3 orders of magnitude, 0.0014 to 1 mM). Each of the 
20 concentrations was tested in a single well, whereas solvent was evaluated in 4 replicate 
wells. Upon addition of test chemical the plates were immediately incubated in a humidified 
atmosphere at 37°C with 5% CO2 for 24 hr.  
 Merck-supplied chemicals were tested similarly, with the following exceptions. 
Preliminary dose-range finding experiments were used to generate 24 hr relative nuclei count 
(RNC) data for each chemical provided (via MultiFlow® — Cleaved PARP Kit, Litron 
Laboratories, Rochester, NY). Concentrations for the definitive experiment were chosen based 
on the RNC results with the intention to test at least one concentration that approached or 
slightly exceeded the MultiFlow assay’s cytotoxicity limit, that is 80% reduction to RNC at 24 hr 
[Bryce et al., 2016]. There were two exceptions, 14n and 16p, compounds that were tested up 
to maximal feasible concentrations due to the low quantity of chemical that could be supplied 
(4.41 and 100 µM, respectively). For the definitive experiments, 10 concentrations of each 
chemical were tested in duplicate wells of a 96 well plate. As described above, the majority of 
chemicals were tested using a square root 2 dilution scheme. Based on data from preliminary 
dose-range finding experiments, some chemicals were tested using finer dilution schemes.  
 
MultiFlow Assay 
 TK6 cells were prepared for analysis using reagents and instructions included in the 
MultiFlow® DNA Damage Kit — p53, γH2AX, Phospho-Histone H3 (Litron Laboratories, 
Rochester, NY). Components and preparation of the MultiFlow working solution have been 
described in detail previously [Bryce et al. 2016, 2017]. At the 4 and 24 hr sampling times, cells 
were resuspended with pipetting, then 25 µL were removed from each well and added to a new 
96-well plate containing 50 µL/well of pre-aliquoted working MultiFlow reagent solution. Mixing 
was accomplished by pipetting the contents of each well several times. After incubation at room 
temperature for 30 min, samples were analyzed via flow cytometry. 
 Flow cytometric analysis was carried out using either a FACSCanto™ II flow cytometer 
equipped with a BD™ High Throughput Sampler or a Miltenyi Biotec MACSQuant® Analyzer 10 
flow cytometer with integrated 96-well MiniSampler device. Stock photomultiplier tube detectors 
and associated optical filter sets were used to detect fluorescence emissions associated with 
the fluorochromes: FITC (detected in the FITC channel, to use BD instrument parlance), PE (PE 
channel), propidium iodide (PerCP-Cy5.5 channel), and Alexa Fluor® 647 (APC channel).  
 Representative bivariate graphs, gating logic, and position of regions were described in 
detail in earlier reports [Bryce et al., 2016, 2017; Bernacki et al., 2016]. Briefly, two biomarker 
measurements, γH2AX and p53, were based on the shift in median channel fluorescence 
intensity relative to same-plate solvent controls. Polyploidy and p-H3 biomarker measurements 
were based on their frequency among other nuclei. Nuclei to counting bead ratios were 
calculated for each sample, and these ratios were used to determine absolute nuclei counts 
(those with 2n and greater DNA-associated propidium iodide fluorescence). Nuclei counts were 
used to derive RNC, and %cytotoxicity was calculated as 100% minus %RNC at 24 hr. 
 
MultiFlow Data Analysis: Pre-Processing 
 Data analyses described herein were restricted to those concentrations that did not 
exceed the MultiFlow assay’s cytotoxicity limit, i.e., the top concentration of each chemical had 
to exhibit ≤ 80% reduction to RNC at the 24 hr time point. This has been described previously 
by Bryce and colleagues [2016, 2017]. The present report differs slightly, such that in addition to 
the 80% maximum cytotoxicity limit noted above, only two concentrations within the cytotoxicity 
range 70-80% were permitted. Finally, except for 14n and 16p as noted above, in the absence 
of excessive cytotoxicity the top concentration was 1 mM or the lowest precipitating 
concentration, whichever was lower.   
 For the GEF, machine learning, and benchmark dose analyses described below, 4 and 
24 hr γH2AX, p53, and p-H3 measurements, and 24 hr polyploidy frequencies, were converted 
to fold-change values by dividing them by the mean value associated with solvent-exposed 
cultures on the same plate (Microsoft Excel 2008, v12.3.6). This was performed for every test 
article concentration that was not excluded due to excessive cytotoxicity or other limits 
described above.  
 Unsupervised clustering analyses benefitted from several transformations. First, feature 
scaling (also known as unity-based normalization) was applied to every test article 
concentration to bring the values into the range 0 to 1 [Jayalakshmi and Santhakumaran, 2011]. 
Second, for each biomarker response and time point combination, fold-change values versus 
normalized concentration curves were used to generate an area under the curve (AUC) value. 
AUC provided a means of converting each biomarker dose-response relationship for every 
chemical into a single value. This was accomplished using Microsoft Excel via the trapezoidal 
rule as described at www.statisticshowto.com/how-to-find-the-area-under-a-curve-in-microsoft-
excel. One (1) was subtracted from every biomarker’s fold-change value before AUC 
calculations were made in order to set the no effect (baseline) value to zero. With this offset in 
place, AUC values were zero or nearly so in the case of no response, positive in the case of an 
increase, and negative in the case of a reduction. Also note that polyploid fold change values 
were transformed with the square root function, a processing step that converted this 
biomarker’s dynamic range to one that more closely approximated that of the other biomarkers 
(found to be advantageous for artificial neural network models, see Bryce et al., 2018). 
 
MultiFlow Data Analysis: Global Evaluation Factors 
 MultiFlow biomarker/time point combinations were compared to GEFs reported by Bryce 
and colleagues [2017]. GEFs for the three clastogen-responsive biomarkers 4 hr γH2AX, 4 hr 
p53, and 24 hr γH2AX, were 1.51-, 1.40-, and 2.11-fold, respectively; GEFs for the three 
aneugen-responsive biomarkers 4 hr p-H3, 24 hr p-H3, and 24 hr polyploidy, were 1.71-, 1.52-, 
and 5.86-fold, respectively; and the GEF for the pan-genotoxicant (clastogen- and aneugen-
responsive) biomarker, 24 hr p53, was 1.45-fold. Meeting or exceeding these interlaboratory-
derived values identified a significant biomarker response at a particular time point. To 
synthesize the results of these multiple comparisons and to make judgments about genotoxic 
potential and MoA, the following rubric was applied. A genotoxic call with a clastogenic MoA 
required two successive concentrations to meet or exceed the GEF for at least two out of four 
clastogen-sensitive biomarkers: 4 hr γH2AX, 4 hr p53, 24 hr γH2AX, and 24 hr p53. A genotoxic 
call with an aneugenic MoA required two successive concentrations to meet or exceed the GEF 
for at least two out of four aneugen-sensitive biomarkers: 4 hr p-H3, 24 hr p-H3, 24 hr 
polyploidy, and 24 hr p53. In cases where both clastogen and aneugen call criteria were met, 
the call was genotoxic with a “mixed” MoA. When the above criteria were not met, the call was 
non-genotoxic under the test conditions. 
 
MultiFlow Data Analysis: Machine Learning Ensemble 
 The development and use of three machine learning models, multinomial logistic 
regression (LR), artificial neural network (ANN), and random forest (RF), was described in detail 
previously [Bryce et al., 2018]. Briefly, these various models utilize 4 and 24 hr MultiFlow data 
fold-change values and predict whether a chemical exhibits genotoxic activity or not, and if 
present whether the genotoxicity occurs via a clastogenic, aneugenic, or clastogenic and 
aneugenic MoA. Each model’s output was synthesized into genotoxicity and MoA calls as 
follows. Genotoxic, with evidence for a clastogenic MoA, required two successive 
concentrations to exhibit clastogen probability scores ≥ 80%, or one concentration to exhibit a 
clastogen probability score ≥ 90%. Genotoxic, with evidence for an aneugen MoA, required two 
successive concentrations to exhibit aneugen probability scores ≥ 80%, or one concentration to 
exhibit an aneugen probability score ≥ 90%. Non-genotoxic was defined as the absence of two 
successive concentrations exhibiting clastogen or aneugen probability scores ≥ 80%, and no 
one concentration exhibiting a clastogen or aneugen probability score ≥ 90%. 
 A majority vote ensemble considered the genotoxicity calls from each of the 3 modeling 
approaches as described above. A simple majority (2 out of 3) was necessary for a summary 
genotoxic call. For most chemicals, MoA predictions were found to be in agreement across 
models. In instances when models showed significant clastogen and aneugen probabilities, the 
chemical was considered genotoxic with evidence for a mixed MoA.  
 
MultiFlow Performance Assessments  
 Training and test set chemicals were evaluated against a priori genotoxicity and MoA 
expectations. This was accomplished via a hybrid strategy that made use of both GEF and 
machine learning predictions. With this approach, an overall genotoxic call was made when 
either the GEF or the machine learning ensemble was positive (see Figure 1). We 
supplemented these analyses by evaluating the performance of the GEF rubric and machine 
learning ensemble on their own.  
 For each strategy described above, performance was assessed by determining the level 
of agreement between expected and observed genotoxicity calls. This was accomplished by 
calculating the percentage of chemicals correctly identified as being genotoxic or non-genotoxic. 
Furthermore, for those agents that were identified as genotoxic, the level of agreement between 
MoA calls was also made by calculating the percentage of compounds that showed expected 
MoA. In the several instances where a priori MoA was either difficult to define or hypothesized 
to be a mixed MoA, any genotoxic MoA prediction was considered correct. In cases where a 
presumably non-genotoxic chemical was identified as genotoxic, any/all associated MoA calls 
were considered incorrect.  
 
Unsupervised Clustering 
 Chemicals that were identified as aneugens by the hybrid GEF and machine learning 
approach were evaluated using JMP software’s unsupervised clustering platform (JMP, 
v12.0.1). As described above, the biomarker response data were first converted to AUC values, 
and when clustering aneugens, the following 7 biomarkers were used as variables: 4 hr γH2AX, 
p-H3 and p53, and 24 hr γH2AX, p-H3, p53 and 24 hr polyploidy. The analysis options were set 
as follows: clustering method = hierarchical; method for calculating distances between clusters 
= “Ward”; data as usual = “Standardize Data”; data visualization = “Dendrogram”, with “two way 
clustering”.  
 Chemicals identified as clastogens by the hybrid GEF and machine learning approach 
were evaluated in a similar manner. However, in this case, the 4 variables were utilized: 4 hr 
γH2AX, 4 hr p53, 24 hr γH2AX, and 24 hr p53.  
 
Benchmark Dose Analyses  
 A subset of the reference genotoxic chemicals (n = 34) were evaluated for in vitro 
micronucleus (MN) formation using TK6 cells from the same treated cultures used in the 
MultiFlow assay. These analyses were conducted at the 24 hr time point, and were 
accomplished via flow cytometric analysis using In Vitro MicroFlow® Kit reagents (Litron 
Laboratories, Rochester, NY). These methods have been reported in detail elsewhere 
[Avlasevich et al., 2006]. For the MN endpoint, concentrations were limited to those that resulted 
in ≤ 55% reduction to relative nuclei counts.  
 The Benchmark Dose (BMD) for continuous data is defined as the dose or exposure that 
results in a predetermined percent change (benchmark response, BMR) in the response rate of 
an adverse effect relative to existing background incidence, generally in the range of 1-10% 
increase in the background [MacGregor et al., 2015]. BMD analyses were performed for the 
subset of 34 chemicals with concurrent MultiFlow and MicroFlow data. Specifically, γH2AX, p-
H3, p53, and in vitro MN dose responses were evaluated using PROAST (v63.3). Values for 
Critical Effect Size (CES, in PROAST notation) of 0.5 (BMR 50%), or 1.0 (BMR 100%, in the 
case of in vitro MN compounds mitomycin C, 4-nitroquinoline 1-oxide, and topotecan) were 
used for covariate BMD analysis for the compounds. The resulting 95% Confidence Intervals 
(CI’s) were used to represent the relative potency of the compound for the endpoint under 
study. After ranking the in vitro MN induction potency of each compound, the data were 
compared with 24 hr γH2AX and 24 hr p53 endpoints for the clastogen group of compounds, 
and 24 hr p-H3 and 24 hr p53 endpoints for the aneugen group of compounds. These 
correlations are represented in cross system plots on a double Log scale [Soeteman-Hernández 
et al, 2016; Bemis et al., 2016]. The analyses were conducted separately for clastogens (n = 21) 
and aneugens (n = 13). 
 
RESULTS AND DISCUSSION 
Tier 1 Analyses: Training Set 
 The 85 reference chemicals that comprise the training set were given a priori 
classifications in regard to their genotoxic potential, as well as their predominant genotoxic MoA, 
clastogenicity or aneugenicity (Table I). Results for several of these agents are presented in 
detail in order to describe prototypical response profiles, and to introduce a new data 
visualization tool. These examples should provide a useful background for interpreting the 
aggregate chemical results that are presented hereafter. 
 Thapsigargin is an inhibitor of the sarco/endoplasmic reticulum Ca++ ATPase [Rogers et 
al., 1995]. A radar plot portrays each biomarker response and time point combination as a 
function of concentration (Figure 2a). As expected for a non-genotoxicant, no substantial 
increases in γH2AX, p-H3, p53 or polyploidization biomarkers were observed, despite that fact 
that it was tested to cytotoxic concentrations (71% cytotoxicity). Thus, it is not surprising that 
neither the GEF rubric or any of the three machine learning models predicted genotoxicity 
(Table II). 
 Treatment of TK6 cells with the reference genotoxicant 4-nitroquinoline 1-oxide resulted 
in a prototypical clastogenic response profile (Figure 2b). The γH2AX biomarker was increased 
at 4 and 24 hr. Whereas p53 activation at the 24 hr time point is a pan-genotoxicity signal, 
activation at 4 hr, as observed here, is quite specific for clastogens [Bryce et al., 2014, 2016]. 
Additionally, 4-nitroquinoline 1-oxide did not increase polyploidization, and the p-H3 biomarker 
was reduced in a dose-dependent manner. Both of these observations provide additional 
evidence of clastogenic as opposed to aneugenic activity. As shown in Table II, the GEF rubric 
and all three of the machine learning models predicted genotoxicity, with a clastogenic MoA.  
 Mebendazole’s aneugenicity has been attributed to microtubule binding [Laclette et al., 
1980]. MultiFlow response data illustrate a typical tubulin binder-induced aneugenic response 
profile (Figure 2c). While anti-γH2AX-associated fluorescence did not increase at either time 
point and p53 translocation was not apparent at 4 hr, marked p53 responses were observed at 
24 hr. Furthermore, robust increases in p-H3 positive events were induced by mebendazole, 
and this was accompanied by polyploidization. GEFs as well as the machine learning ensemble 
identified this compound as genotoxic, with evidence for an aneugenic MoA. 
 Crizotinib is another aneugen that is instructive for several reasons. Crizotinib is a potent 
inhibitor of c-Met and ALK (anaplastic lymphoma kinase), with cell-based assay IC50 values in 
the low nM range [Awad and Shaw, 2014].  Even so, there is evidence that the agent’s in vitro 
aneugenic activity may be related to off-target effects on aurora kinase(s) [Kong et al., 2018]. 
Data presented in Figure 2d support this view, as it generated response profiles that are similar 
to several confirmed aurora kinase inhibitors tested in the MultiFlow assay (e.g., ZM-447439 
and tozasertib). As with many tubulin binders, p53 activation and polyploidization were observed 
at the 24 hr time point. In the case of this kinase inhibitor, polyploidization was especially robust, 
and was evident well before the assay’s cytotoxicity limit was reached (i.e., 8-fold increase in 
polyploidy at 59% cytotoxicity). Unlike tubulin binders, the proportion of p-H3-positive events 
was not elevated. Rather, at the highest concentrations tested, severe decreases were 
observed. These observations are consistent with aurora kinase inhibition, as this activity would 
be expected to repress serine 10 phosphorylation of histone H3 on mitotic chromosomes 
[Crosio et al., 2002]. Despite the response profile being quite different than spindle poisons, 
both the GEF rubric as well as all three of the machine learning models identified crizotinib as 
genotoxic, with evidence for an aneugenic MoA (Table II). 
 Results from the tier 1 data analyses are presented for all 85 training set chemicals in 
Table II. For the combined GEF plus machine learning ensemble, the concordance between a 
priori expected and observed genotoxicity calls was 99%. For those agents with a genotoxic 
call, the agreement with expected MoA was 98%. In both cases, the one mischaracterized 
agent was imatinib mesylate (identified as a clastogen). Table II also provides performance 
metrics for the machine learning ensemble and GEFs used in isolation. The most obvious 
difference between the two is that the former was effective for both genotoxicity calls and MoA 
predictions (at least with a training set size of 85 chemicals), while the GEF rubric showed a 
lower level of agreement between expected and observed genotoxic activity calls (i.e., 93% 
concordance), especially for clastogens. Note: Supplemental file 1a-c provides Manhattan-type 
plots that show machine learning probabilities for each of the 85 chemicals at every 
concentration tested. 
  
Tier 1 Analyses: Test Set 
 With promising results evident for 85 training set chemicals, work with compounds that 
were not used to devise the GEF rubric or the machine learning models were tested in the 
MultiFlow assay. The results from tier 1 analyses are presented in Table III. For this set of 40 
diverse chemicals, the combined GEF plus machine learning ensemble resulted in 88% 
agreement between expected and observed genotoxicity calls.  
 Three suspected genotoxicants were not identified as such: 6f, 13m, and 14n. While 6f 
was an anticipated aneugen, it was not observed to affect any of the aneugen-sensitive 
biomarkers, despite the fact that analyses included concentrations that induced up to 63.8% 
cytotoxicity. Compound 14n was also classified a priori as aneugenic, and in this case only one 
aneugen biomarker was slightly induced: 4 hr p-H3 was increased by 1.39-fold at the highest 
concentration tested, 4.41 µM. This false negative result for 14n should be qualified to some 
degree, since cytotoxicity at the highest feasible concentration tested was 48.7%, well below the 
assay’s cytotoxicity limit of 80%. The third false negative result, 13m, is also noteworthy. 
Whereas 6f and 14n showed slight to nil biomarker responses, 13m caused robust increases 
that exceeded biomarker GEFs for 4 hr p-H3 and 4 hr γH2AX across several consecutive 
concentrations, as well as 24 hr polyploidy at the highest concentration (Figure 3a). This 
response profile was not observed in the 85 chemical training set, and consequentially the GEF 
rubric was not developed with this in mind, and the machine learning models have no 
experience with this pattern.  
 Tier 1 mischaracterized two non-genotoxicants as genotoxic: 2b and 12L. In the case of 
2b (a.k.a., sodium diethyldithiocarbamate trihydrate), it should be noted that this compound has 
been shown to induce cytogenetic damage in both CHO and TK6 cells [Hilliard et al., 1998; 
Galloway et al., 1998; Greenwood et al., 2004], and DNA double strand breaks in rat 
hepatocytes [Storer et al., 1996], but only at concentrations deemed overly cytotoxic by current 
testing standards. There are at least two biologically plausible causes for indirect effects leading 
to in vitro DNA damage: diethyldithiocarbamate chelates copper and zinc, and it is a potent 
inhibitor of superoxide dismutase [Heikkila et al., 1976; Nicotera et al., 1989]. 
 Of the chemicals identified as genotoxic, tier 1 analyses were also used to predict their 
genotoxic MoA. As shown in Table III, 88% agreement was observed between expected and 
observed calls. One compound, 16p, showed mixed activities, as both clastogen and aneugen 
biomarker responses were detected. This was an expected result, as 16p has an 
azobenzimidazole structure that was previously observed to induce premature centromere 
separation at metaphase in addition to induction of micronuclei and structural aberrations. 
MultiFlow biomarker results for this atypical agent are shown in Figure 3b. The three chemicals 
with misidentified MoA included the aneugen call for ciprofloxacin, a fluoroquinoline class 
antibiotic that was expected to exhibit clastogenic activity based on its reported topoisomerase II 
inhibitor activity, and the two a priori non-genotoxicants discussed above (i.e., 2b and 12L; both 
identified as clastogens). 
 Overall, the high concordance values speak to the generalizability of the combined GEF 
and machine learning ensemble to detect genotoxicants, and to furthermore provide an 
indication of genotoxic MoA. As with the training set, GEF and machine learning were also 
considered in isolation. Similar to the training set, these analyses suggest the use of the current 
GEF rubric alone is somewhat suboptimal, as agreement between expected and observed 
genotoxicity calls fell to 75%, a result that is largely attributable to false negative calls. 
Supplemental file 2a-c provides Manhattan-type plots that show machine learning probabilities 
for each of the 40 test set chemicals at every concentration evaluated. 
 
Tier 2 Analyses 
 A set of 21 a priori aneugens and mixed MoA chemicals that were identified as such in 
tier 1 analyses were evaluated via unsupervised hierarchical clustering using 4 and 24 hr 
MultiFlow biomarker data that were each converted to a single AUC value. The resulting 
groupings are presented in Figure 4 in the form of a two dimensional dendrogram. The clade 
denoted “TB” was entirely comprised of tubulin binders. Note that whereas the exact 
mechanism of test agent 17q is not known, it is a benzimidazole-containing structure and 
therefore expected to have tubulin-binding properties. The other clear grouping is denoted “KI”, 
a clade that included each of the presumptive mitotic kinase inhibitors that were tested: AMG 
900, crizotinib, tozasertib, hesperadin, ZM-447439, and 10j. 
 The set of 46 a priori clastogens that were identified as such in tier 1 analyses were also 
evaluated via unsupervised clustering using the 4 clastogen-responsive biomarkers. The results 
are shown in Figure 5. For this set of diverse clastogens, it is less obvious that clusters formed 
around different molecular targets. That said, the clade identified as “TI” was highly enriched for 
topoisomerase inhibitors (6/8), and the “C-L” grouping was enriched for DNA cross-linking 
agents (5/9). 
 Taken together, a second tier that consists of unsupervised hierarchical clustering 
appears to complement genotoxic potential and MoA analyses, as it provides useful information 
about likely molecular targets. This is especially true in the case of delineating aneugens that 
target mitotic kinases versus those that interfere with tubulin polymerization.  
 
Tier 3 Analyses 
 BMD metrics served as a basis for tier 3, analyses that were conducted to determine 
whether MultiFlow biomarker(s) could provide a reliable indication of chemicals’ genotoxic 
potency. The advantage of using BMD-derived potency metrics has been previously discussed 
by Soeteman-Hernández and colleagues [2015, 2016]. As shown in Figures 6 and 7, the BMDs 
in the MultiFlow endpoints were plotted against micronucleus response BMDs on a double-log 
scale. As opposed to representing correlation with a numerical coefficient value, a linear 
relationship with intercept zero equals a straight line in a double-log plot. Therefore, two lines 
with unity slope have been drawn on each correlation plot in such a manner that the majority of 
the BMD confidence intervals are encompassed between the lines. The distribution of BMD 
positions within the two lines show approximate linearity, differing by a proportionality constant. 
Furthermore, the vertical distance between the two lines translates into an uncertainty margin 
given by the estimation of a BMD on the y axis based on a specified BMD on the x axis, and 
vice versa. The uncertainty margin is used as a measure of correlation between two endpoints.       
 For the aneugens, when comparing MN induction to p53 responses, the cross system 
plots show good correlation, with the majority of the compounds located between the two lines 
(Figure 6). Taking the microtubule binder nocodazole as an example, the horizontal dashed line 
intersections with the sloped dashed lines may be considered as the respective upper and lower 
bounds of the uncertainty range for the in vitro MN endpoint. The intercepts of approximately -3 
and -1 on the Log scale correspond to lower and upper bounds of 10-3 = 0.001 and 10-1 = 0.1 
µM, respectively. Hence, the in vitro MN BMD for nocodazole is estimated to lie between 0.001 
and 0.1 µM considering an uncertainty margin of approximately 1 Log. In fact, the in vitro MN 
potency for nocodazole in the dataset represented in Figure 6 has both BMDL and BMDU either 
side of -2 Log, and hence within the estimated potency of -3 Log and -1 Log estimated from the 
p53 response. The MN vs. 24 hr p-H3 system plot also indicates the BMDs for the majority of 
compounds in both systems are proportionally related (Figure 6), however the two lines are 
drawn further apart than the MN vs. 24 hr p53 system (i.e., 2 logs versus 1 log). In both cases, 
MN vs. p53 and MN vs. p-H3, the data are randomly scattered with good correlation.  
 For the clastogens, good correlation is observed for MN vs. γH2AX and MN vs. p53, with 
data randomly scattered between the two diagonal lines of the unity slopes, with distances of 
approximately 3 Log, and 2 Log respectively for each system (Figure 7).  
 The correlations observed here are consistent with those of other genotoxicity endpoints 
which have been compared using similar methodologies. Bemis and colleagues [2016] obtained 
an uncertainty margin of approximately 1.5 Log when comparing the in vitro MN responses 
against in vivo MN responses for a group of 7 clastogens. Similarly, Soeteman-Hernández et al. 
[2015] assessed the ability to predict in vivo MN potency from in vitro MN data. BMD confidence 
intervals span 2 orders of magnitude, with in vivo BMD confidence intervals generally smaller 
than those from in vitro studies.  
 
Conclusions 
 The MultiFlow DNA Damage Assay’s ability to predict chemicals’ in vitro genotoxic 
potential and MoA was demonstrated with an external test set of 40 largely pharmaceutical-
centric compounds. Whereas the GEF and associated rubric exhibited high specificity and 
accurate MoA predictions, it provided lower sensitivity to detect genotoxicants relative to a 
machine learning ensemble. A hybrid strategy whereby GEFs and machine learning are used to 
make calls appears to be advantageous. This approach should allow for the identification of 
most genotoxicants while training set data are still being expanded. Furthermore, even as data 
used to build prediction algorithms become more extensive, concurrent use of the GEF rubric 
represents a safety net of sorts, as it is capable of highlighting biomarker response patterns that 
the machine learning model(s) may not have encountered. In this respect, the hybrid strategy 
should be useful to novice laboratories, as well as established groups as they begin 
investigating new chemical spaces that have not been tested, or that are currently 
underrepresented in the training set. The compound 13m is a useful example. Although the 
GEF rubric did not classify the novel response profile as genotoxic, the fact that three 
biomarkers were elevated over their respective GEFs serves to suggest that the machine 
learning algorithms require additional training in this chemical space if the responses are indeed 
caused by bona fide genotoxic activity that needs to be reliably detected.  
 Unsupervised clustering is able to group certain genotoxicants with the same or similar 
molecular targets based on multifactorial biomarker response patterns. This was especially 
successful with aneugens that were clustered into tubulin binder and kinase inhibitor groups. 
While these analyses do not offer proof of molecular targets, they do represent a powerful 
hypothesis-generating tool, one that could be used to efficiently design the necessary follow-up 
test(s) aimed at directly and conclusively identifying molecular target(s) responsible for in vitro 
genotoxicity  
 With respect to the BMD analyses reported herein, the strong correlation of MultiFlow 
biomarkers to bona fide genomic damage in the form of MN provides assurances of the 
relevance of the new assay’s endpoints. Furthermore, the correlations suggest that potency 
determinations based on MultiFlow endpoints, at least on a rank-order basis, are likely 
comparable to those derived from the MN assay. This bolsters the use case whereby the 
constellation of MultiFlow assay biomarkers serve as a reliable genotoxicity screening tool that 
is predictive of in vitro MN formation, with the benefit of providing more mechanistic information. 
Finally, dose-response analyses such as these are worth pursuing further because they reflect 
the paradigm shift that has been transitioning genotoxicity away from a simple binary yes/no 
characteristic to a quantitative metric that has the potential to better inform risk assessments as 
margin of exposure and other toxicological principles can be considered [Pottenger and 
Gollapudi, 2009, 2010; Gollapudi et al., 2013; Johnson et al., 2014; MacGregor et al., 2015a,b; 
Dearfield et al., 2017]. 
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FIGURE LEGENDS 
Figure 1. Flow chart representing a tiered MultiFlow assay data analysis pipeline. With this 
strategy chemicals are evaluated for their genotoxic potential and genotoxic mode of action (tier 
1), insights into molecular target are provided by unsupervised clustering (tier 2), and finally 
potency metrics are generated (tier 3).  
 
Figure 2. Radar plots show MultiFlow assay data for seven biomarker/time point combinations 
and for each of four chemicals: thapsigargin, 4-nitroquinoline 1-oxide (4NQO), mebendazole, 
and crizotinib. The biomarker data are expressed as fold-increase over mean solvent control on 
the same plate, and each chemical concentration appears as a different colored line. The top-
most endpoint (24 hr p53, at 12 o’clock) is a pan-genotoxic biomarker, whereas the biomarkers 
arranged on the right side of the graph are responsive to clastogens and those arranged on the 
left are responsive to aneugens.  
 
Figure 3. Radar plots show MultiFlow assay data for seven biomarker/time point combinations 
and for each of two chemicals: Merck-supplied test compounds 13m and 16p. The biomarker 
data are expressed as fold-increase over mean solvent control on the same plate, and each 
chemical concentration appears as a different colored line. Same format as Figure 2.  
 
Figure 4. Unsupervised clustering results are shown as a two dimensional dendrogram for 21 
chemicals that were identified as exhibiting aneugenic activity. As described in Materials and 
Methods, each biomarker dose response was converted to an area under the curve for this 
analysis. The abbreviations TB (tubulin binder) and KI (kinase inhibitor) are used to denote 
clades with chemicals that are known to exhibit these activities. 
 
Figure 5. Unsupervised clustering results are shown as a two dimensional dendrogram for 46 
chemicals that were identified as exhibiting clastogenic activity. As described in Materials and 
Methods, each biomarker dose response was converted to an area under the curve for this 
analysis. The abbreviations TI (topoisomerase inhibitor) and C-L (cross-linker) are used to 
denote clades that are enriched for chemicals known to exhibit these activities. 
 
Figure 6. Left panel: BMD analyses of aneugen compounds represented in cross system plots 
with BMD50 confidence intervals for in vitro MN against BMD50 24 hr p-H3 responses in TK6 
cells, with both x and y axes representing Log10 concentration of compounds in µM. The 
dashed parallel lines are drawn in such a way that encompasses most of the confidence 
intervals. Compound ‘car’ falls outside the trend with unbound confidence intervals in the 24 hr 
p-H3 endpoint. Right panel: BMD50 confidence intervals for in vitro MN against BMD50 24 hr 
p53 responses in TK6 cells, with both x and y axes representing Log10 concentration of 
compounds in µM. Dashed parallel lines encompassing most of the BMDs, similarly to the left 
panel correlation plot. Compounds ‘gli’ and ‘des’ lie outside the general observed trend, with 
unbound upper confidences interval in the 24 hr p53 endpoint. Dashed horizontal lines obtain 
the uncertainty range with corresponding circles intercept with the x axis predicting the BMD50 
for in vitro MN response. See Table I for compound abbreviations. Abbreviation: BMD, 
Benchmark Dose. MN, micronucleus. 
 
Figure 7. Left Panel: BMD analyses of clastogen compounds represented in cross system plots 
with BMD50 confidence intervals for in vitro MN (with the exception of mmc, nqo and top) 
versus BMD50 24hr H2AX responses in TK6 cells, with both x and y axes representing Log10 
concentration of compounds in µM. The dashed parallel lines are drawn in such a way that 
encompasses all of the confidence intervals. Right Panel: BMD50 confidence intervals for in 
vitro MN (with the exception of mmc, nqo and top) versus BMD50 24hr p53 responses in TK6 
cells, with both x and y axes representing Log10 concentration of compounds in µM. Dashed 
parallel lines encompassing most of the BMDs. Compound ola lies outside the general observed 
trend, with an unbound upper confidence interval in the p53 endpoint. Compound cis displays 
an unbound upper confidence interval in the p53 endpoint. See Table I for compound 
abbreviations. Abbreviation: BMD, Benchmark Dose. MN, micronucleus. 
 
 
 
 
 
 
  
